Search clinical trials for: immunogenicity

Total 3444 results

International Vaccine Institute
Indian Council of Medical Research; National Institute of Cholera and Enteric... and other collaborators

Completed

Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata

Cholera

India
Avant Immunotherapeutics

Completed

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

Typhoid Fever

United States
Society for Applied Studies
All India Institute of Medical Sciences, New Delhi; National Institutes of... and other collaborators

Completed

Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants

Rotavirus Infections

India
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

Hepatitis B

Austria
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

Hepatitis B

Belgium, Canada, Sweden
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Hepatitis B

Denmark, Belgium
Novartis
Novartis Vaccines

Completed

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Japanese Encephalitis | Rabies | Pre-Exposure Prophylaxis

Thailand
French National Agency for Research on AIDS and...
Aventis Pharmaceuticals

Completed

AIDS Vaccine Study Comparing Immunogenicity and Safety of 3 Doses of Lipopeptides Versus Placebo in Non Infected HIV Volunteers

HIV Infections

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

Healthy

Australia
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (MSP3LSP)

Malaria

Burkina Faso
African Malaria Network Trust

Unknown

Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine

Malaria

Mali
Novartis
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

Influenza

Poland
Novartis
Novartis Vaccines

Completed

Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years

Encephalitis, Tick-Borne

Germany
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008

Seasonal Influenza | Vaccine

Germany
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Prevention | Pandemic Influenza | Pandemic Influenza Vaccine

China
Institute of Child Health
Great Ormond Street Hospital for Children NHS Foundation Trust

Completed

Conjugate Pneumococcal Vaccine in Ataxia Telangiectasia (AT)

Ataxia Telangiectasia (AT)

United Kingdom
University of Oxford

Completed

Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine

TB

United Kingdom
African Malaria Network Trust

Unknown

Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine

Malaria

Gabon
African Malaria Network Trust

Unknown

Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545])

Malaria

Mali
National Cancer Institute (NCI)

Completed

Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 Infection

HIV Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants

Cutaneous Leishmaniasis

United States
National Cancer Institute (NCI)

Completed

Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection

Acquired Immunodeficiency Syndrome | HIV Infection

United States
MedImmune LLC

Completed

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

Influenza
Biogen

Completed

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy (SAFE)

Multiple Sclerosis

Sweden
Nabi Biopharmaceuticals
Public Health England

Completed

StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery

Staphylococcal Infections

United Kingdom
Nabi Biopharmaceuticals

Completed

StaphVAX Immunogenicity in Orthopedic Implant Patients

Staphylococcal Infections | Joint Prosthesis

United States
MedImmune LLC

Completed

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Influenza

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Prevenar Immunogenicity in High Risk Children

Vaccines, Pneumococcal Conjugate Vaccine
Epimmune
Pharmexa A/S; Pharmexa-Epimmune

Unknown

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART) (EP1090)

HIV Infections

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
MedImmune LLC

Completed

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Healthy

United States
Sinovac Biotech Co., Ltd
Centers for Disease Control and Prevention, China

Completed

Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine

Prevention | Pandemic Influenza
Queen Elizabeth II Health Sciences Centre

Unknown

The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Pertussis
Johann Wolfgang Goethe University Hospital
Allergopharma GmbH & Co. KG

Completed

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

Immunotherapy

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

Melanoma

Germany
Cytos Biotechnology AG

Completed

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

Malignant Melanoma

Switzerland
European Malaria Vaccine Initiative

Unknown

GMZ2-Aluminum Hydroxide Phase I, Tübingen

Malaria

Germany
Norwegian Institute of Public Health

Completed

Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine

Pertussis | Tetanus | Diphtheria | Polio

Norway
University of Oxford

Completed

A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers

TB

United Kingdom

3

Subscribe